FDA Clearance Tracker · P250024-S002
Trilogy Transcatheter Heart Valve System
Last checked: Nov 20, 2026Latest source record: May 18, 2026 (this decision)Source: openFDAMethods & limitations
Decided
May 18, 2026
Approved
Time to decision
32 days
Received Apr 16, 2026. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track No User Fee
Device class
Class III
The decision
- FDA number
- P250024-S002
- Device name
- Trilogy Transcatheter Heart Valve System
- Applicant
- JenaValve Technology, Inc.
- Applicant location
- Irvine, CA
- Received
- Apr 16, 2026
- Decided
- May 18, 2026
- Decision
- Approved
- Supplement type
- Normal 180 Day Track No User Fee
- Reason for supplement
- Postapproval Study Protocol
- Original approval
- P250024
Device type
- Device class
- Class III
- Specialty
- CardiologyInterventional Cardiology
FDA's approval statement
As written in FDA's record.
approval for the protocol for the Registry-Based Real-World Use Surveillance post-approval study (PAS)
Source documents
Other decisions for JenaValve Technology, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- Trilogy Transcatheter Heart Valve SystemBreakthroughPMA
P250024 · Decided Mar 17, 2026 · 260 days after receipt
Device type: Aortic valve, prosthesis, percutaneously delivered (NPT) · Cardiology
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.